Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitogen-activated ERK kinase cascade, also known as the RAF–MEK–ERK or MAPK/ERK pathway, is a highly conserved signal transduction pathway that relays extracellular signals from cell surface receptors to the nucleus. This cascade plays a central role in regulating key cellular processes such as proliferation, differentiation, survival, gene expression, and apoptosis. Aberrant activation of this pathway is implicated in cancer development (tumorigenesis), developmental disorders ("RASopathies"), schizophrenia spectrum disorders, bipolar disorder, migraines, among others. Due to its central role in cell fate decisions—and frequent dysregulation in cancers—the MAPK/ERK pathway has been extensively targeted pharmacologically.
Inhibition of RAF, MEK, or ERK kinases to block downstream signaling.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated ERK kinase cascade (MAPK/ERK Pathway).